J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and ...

5 This European regulatory review follows the file acceptance by the US FDA on 8 January 2025 for the new prefilled syringe presentation, continuing GSK’s commitment to providing solutions to ...

If approved, the new presentation will offer a convenient administration option to healthcare professionals Globally, up to 1 in 3 adults will develop shingles in their lifetime 1,2,3,4 Over 25 ...

The University of Oxford and GSK are to work on a vaccine to target cells in the pre-cancerous stage (PA) Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to ...

If approved by the EMA, this new option could streamline the vaccination process in clinical settings across Europe. GSK is a global biopharma company focused on uniting science, technology ...

when the partners teamed up to launch a new molecular and computational medicine institute. That collaboration formed on the back of a five-year, $40 million investment from GSK and focuses on ...

GSK)'s vaccine for shingles prevention. This new syringe presentation is designed to simplify the administration process for healthcare providers by eliminating the need to mix a powder and liquid ...

Get Our Latest Stock Report on GSK GSK Stock Up 0.8 % GSK opened at $35.35 on Friday. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The firm’s 50 day simple moving average is ...

This European regulatory review follows the file acceptance by the US FDA on 8th January, 2025 for the new prefilled syringe presentation, continuing GSK’s commitment to providing solutions to ...